Grants Search Results

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

Through this partnership with the Children's Cancer Foundation, proceeds from St. Baldrick's head-shaving events in Hong Kong support life-saving childhood cancer research in Hong Kong. The project supported by this grant is a multicenter clinical study testing the best treatment strategy for Chinese children with Acute Lymphoblastic Leukemia. It started from 2008 and completed at the end of 2012. All the hospitals treating children with cancer in Hong Kong participated in this study, and 12 other centers in mainland China also joined the study. They performed a special test on the patients to find any residual leukemia cells in the body after initial chemotherapy treatment in the first 3 months of treatment. The special tests included “flow cytometry for leukemia specific antigen’ and “Quantitative Polymerase Chain Reaction for leukemia DNA”.

Based on progress to date, Dr. Federman was awarded a new grant in 2012 to fund an additional two years of this Scholar award. We already have many powerful drugs to treat cancer but lack the means to deliver them directly to the intended targets (cancer cells), and as a result, cancer patients suffer significant side effects. Dr. Federman tests new ways of delivering anti-cancer treatments more directly using nanoparticles programmed to recognize particular cancer cells.

This grant helps provide staffing to ensure that more kids can be treated on clinical trials, their best hope for a cure, at this institution. A Clinical Research Associate is involved not in the child's treatment, but in the opening of clinical trials and coordinating the collection and submission of bodily tissues and information for each child on a clinical trial. Without these crucial functions, which are often hard to fund, clinical trials cannot continue to advance toward cures, and children are not offered the most up-to-date treatment options.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

The goal of this proposal is to identify tumor suppressor genes that are "turned off" by DNA methylation and contribute to the formation of Ewing Sarcoma, a type of bone cancer that affects teenagers and young adults. This study searches for a better understanding of Ewing Sarcoma and the development of better treatments.

Based on progress to date, Dr. Arvanitis was awarded a new grant in 2011 to fund an optional third year of this fellowship. Osteosarcoma is the most common pediatric bone cancer, which frequently spreads (or metastasizes) to the lung and is then often fatal. Dr. Arvanitis is studying the role of transendothelial migration in osteosarcoma, with the ultimate goal of developing therapies against metastases in pediatric cancers.

The Ewings sarcoma family of tumors (ESFTs) is the second most common cancer of bone and soft tissue in children, and has a 20-30% overall survival rate in those children with widespread disease. Dr. Dela Cruz is working to understand the pathways involved in the development of ESFTs, which will be essential to discovering new molecular targets to treat and cure these patients.

Based on progress to date, Dr. Mulcahy-Levy was awarded a new grant in 2011 to fund an optional third year of this fellowship. Understanding how cancer cells die is important in designing new therapies and improving the effectiveness of currently used therapies to cure childhood cancers. One element of cell death is called autophagy, a system the cell uses to break down as it dies, the focus of Dr. Mulcahy-Levy's project.

This research focuses on hematopoietic progenitor/stem cell (HPC) transplantation. (These stem cells are not embryonic; they are present in everyone's bone marrow and can be harvested from donors.) Dr. Parekh is working on methods to expand HPC to facilitate the use of cord blood and the use of gene therapy to treat leukemia, an important step toward a cure.

Based on progress to date, Oren Becher, M.D., AmWINS St. Baldrick's Scholar, was awarded a new grant in 2012 to fund an additional two years of this Scholar award. Brainstem glioma is a rare subtype of brain tumor found mostly in children, which cannot be cured with today's treatments. Dr. Becher’s research suggests that one major obstacle for progress in the treatment of these brain tumors is limited drug delivery due to the blood-brain-barrier, a protective mechanism that prevents the delivery of toxic chemicals into our brains (in this case- the cancer drugs). Dr. Becher is working with genetic models to find new ways to improve the delivery of cancer drugs to these brain tumors.

This grant is named for AmWINS, a wholesale insurance holding company, which has raised more than $1 million for childhood cancer research through the St. Baldrick's Foundation.

Based on progress to date, Dr. Chang was awarded a new grant in 2012 to fund an additional two years of this Scholar award. One subtype of pediatric leukemia that continues to have a poor prognosis is Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ALL). Dr. Chang is researching a unique protein called survivin, in hopes of developing it as a new target for future therapy for Ph+ALL patients.

Based on progress to date, Dr. Lee was awarded a new grant in 2012 to fund an additional two years of this Scholar award. Natural killer cells (NK cells), one of the white blood cells of our immune system, have the ability to kill several types of cancers in children, including AML, neuroblastoma, osteosarcoma, and Ewing's sarcoma. Dr. Lee's research involves more effective ways to use NK cells to fight childhood cancers.

Acute myeloid leukemia (AML) is a potentially deadly form of childhood leukemia. Dr. Vaiselbuh is studying how AML cancer cells resist chemotherapy with the goal of finding a new strategy for treatment of childhood myeloid leukemia.